Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Saini, Kamal S; Lanza, Carlo; Romano, Marco; de Azambuja, Evandro; Cortes, Javier; de Las Heras, Begoña; de Castro, Javier; Lamba Saini, Monika; Loibl, Sibylle; Curigliano, Giuseppe; Twelves, Chris; Leone, Manuela; Patnaik, Mrinal M

Saini, Kamal S; Lanza, Carlo; Romano, Marco; de Azambuja, Evandro; Cortes, Javier; de Las Heras, Begoña; de Castro, Javier; Lamba Saini, Monika; Loibl, Sibylle; Curigliano, Giuseppe; Twelves, Chris; Leone, Manuela; Patnaik, Mrinal M.

Saini KS; Covance Inc, Princeton, NJ, USA.
Lanza C; East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Romano M; Covance Inc, Princeton, NJ, USA.
de Azambuja E; Covance Inc, Princeton, NJ, USA.
Cortes J; Institut Jules Bordet, Brussels, Belgium.
de Las Heras B; Université Libre de Bruxelles (U.L.B), Brussels, Belgium.
de Castro J; IOB Institute of Oncology, Quiron Group, Madrid, Spain.
Lamba Saini M; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Loibl S; Medica Scientia Innovation Research, Ridgewood, NJ, USA.
Curigliano G; Covance Inc, Princeton, NJ, USA.
Twelves C; Madrid Medical Doctors Association, Madrid, Spain.
Leone M; La Paz Hospital, Madrid, Spain.
Patnaik MM; HistoGeneX, Antwerp, Belgium.

Br J Cancer ; 123(5): 694-697, 2020 09.

Article in English | MEDLINE | ID: covidwho-612104

ABSTRACT

ABSTRACT

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Subject(s)

Antineoplastic Agents/therapeutic use; Betacoronavirus; Coronavirus Infections/drug therapy; Coronavirus Infections/immunology; Drug Repositioning/methods; Pneumonia, Viral/drug therapy; Pneumonia, Viral/immunology; Adrenal Cortex Hormones/therapeutic use; Anticoagulants/therapeutic use; Antineoplastic Agents/pharmacology; COVID-19; Coronavirus Infections/physiopathology; Coronavirus Infections/virology; Humans; Immunologic Factors/therapeutic use; Inflammation/drug therapy; Interleukin-6/antagonists & inhibitors; Pandemics; Pneumonia, Viral/physiopathology; Pneumonia, Viral/virology; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Protein Kinase Inhibitors/therapeutic use; SARS-CoV-2; Treatment Outcome; Vascular Endothelial Growth Factor A/antagonists & inhibitors; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Drug Repositioning / Betacoronavirus / Antineoplastic Agents Type of study: Prognostic study Limits: Humans Language: English Journal: Br J Cancer Year: 2020 Document Type: Article Affiliation country: S41416-020-0948-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google